IPO Pro - "The Ultimate Resource for IPOs"
Don't risk buying another IPO without IPO Pro.
Get your FREE TRIAL now.
PEPG News
Archived Headlines
- Neuromuscular disease biotech PepGen prices IPO at $12, below the range 05/06/22
- Neuromuscular disease biotech PepGen sets terms for $101 million IPO 05/02/22
- Biotech IPOs struggle to tread water amid challenging market conditions 04/27/22
- Neuromuscular disease biotech PepGen files for a $115 million IPO 04/18/22
US IPO Week Ahead: No IPOs in the short holiday week
There are currently no IPOs scheduled for the short Independence Day week. The calendar may be quiet, but you can still stay on top of the IPO market by reading our updated 2Q 2022 US IPO Market Review, which provides detailed analysis of US IPO activity...read more
Updated: Renaissance Capital's 2Q 2022 US IPO Market Review
US IPO Market Posts Its Slowest 2Q Since the Great Recession Just 21 IPOs raised $2.1 billion in the US IPO market’s slowest second quarter since 2009. Issuance was sluggish from the start and pulled back further in late May, as recession fears were heightened by record inflation...read more
Renaissance Capital's May IPO Market Update
Seven IPOs raised a combined $1.1 billion in May, led by eyecare giant Bausch + Lomb (BLCO), one of the month’s three $100+ million IPOs. The group was joined by the year’s first direct listing, US cannabis producer Bright Green (BGXX). Remaining activity came from small issuers, ...read more
US IPO Weekly Recap: Bausch + Lomb deal headlines a 3 IPO week
The IPO market showed signs of life after a fairly quiet April, with three IPOs and two SPACs this past week. While there were only two new IPO filings, a few large deals in the pipeline updated their prospectuses, including Corebridge Financial...read more